Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Aventis Pharma S.a.

Rhone-poulenc Rorer S.a.

UniversitÉ Paris Descartes

Assistance Publique-hopitaux De Paris

Genethon

Université D'evry-Val-d'essonne

Institut Gustave Roussy

UniversitÉ De Paris

Institut De Recherche Pour Le Developpement (ird)

Sorbonne Université

Centre National De La Recherche Scientifique-cnrs

Universite Paris Cité

Inserm (institut National De La Sante Et De La Recherche Medicale)

Daniel Scherman

Pierre Wils

Antoine Kichler

Jean-Michel Rozet

Xavier Gerard

Josseline Kaplan

Isabelle Perrault

Bertrand Schwartz

M Arnold Munnich

Joël Crouzet

Catherine Dubertret

Gerardo Byk

Béatrice Cameron

Jo&euml;l Crouzet

Jean-Paul Behr

Barbara Demeneix

Pascal Bigey

Françis Blanche

B&eacute;atrice Cameron

Lluis M Mir

Jean-Serge Remy

Nathalie Mignet

Didier Gourier

Michel Bureau

Jean Herscovici

Bruno Viana

Beatrice Cameron

Reinhard Fleer

Francine Behar-Cohen

Joel Crouzet

Serge Maitrejean

Arnold Munnich

G&eacute;rardo Byk

Anne-Marie Darquet

Michel Bessodes

Christophe Marcireau

Philippe Deloron

Johanne Seguin

Bruno Pitard

Aurelie Bessiere

Otmane Boussif

Quentin Le Masne De Chermont

Jean-Pierre Jolivet

Corinne Chaneac

Sylviane Giorgi-Renault

Nicaise Tuikue Ndam

Virginie Escriou

Isabelle Tranchant

Corinne Marie

Christian Girard

Guy Chabot

Cyrille Richard

Fran&ccedil;is Blanche

Thomas Maldiney

Yoran Beldengrun

Vincent Pierre-Marie Boudy

Mojgan Mergny

Franck Lezoualch

Stéphanie Desbene-Finck

Fabienne Sylvie Pelle

David Benezra

Carole Bloquel

Christophe Masson

Barbara Wetzer

Mickaël Quiviger

Sedami Ursula Alix Carine Gnidéhou

Marlène Testud

Raphaël Labruere

Philippe Helissey

Fran&ccedil;oise Leclerc

Yongmin Zhang

Sédami Ursula Alix Carine GNIDÉHOU

Aurélie Bessiere

Fabienne Julie Pelle

Didier Louis Gourier

Joel Couzet

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A&#x3e;G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c. 2991+1655 A&#x3e;G CEP290 mRNA.

Methods for the treatment of Leber congenital amaurosis

The present invention relates to gelling compositions, which changes from liquid state to gel state in function of temperature comprising: at least a poloxamer or mixture of poloxamers; at least a gelling agent; and at least an anticancer agent. Said compositions are advantageously used for local administration of an anticancer agent. Said compositions are useful for size-reduction of a tumour before surgical removal of said tumour, for preventing tumour recurrence after surgical removal of a tumour, and/or treating small tumours. They are therefore useful for the treatment of cancer, preferably a cancer of a wall of the digestive system or a gynaecologic cancer. The present invention also relates to a method for preparing said gelling compositions.

Gelling compositions for treating malignant tumours and/or preventing tumour recurrence

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A&#x3e;G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2991+1655 A&#x3e;G CEP290 mRNA.

Multimodal optical and magnetic resonance imaging methods based on the use of persistent luminescence nanoparticles. Use of mesoporous persistent luminescence &#x3c;&#x3c;core-shell&#x3e;&#x3e; complexes for theranostic applications.

Persistent luminescence nanoparticles excitable in situ for in vivo optical imaging, in vivo multimodal optical&#x2014;MRI imaging, and theranostics

The present invention relates to 4-azapodophyllotoxin analogs of formula (I) in which X, R, R, R, Rand Ar are as defined in claim, preferably a pharmaceutically acceptable salt thereof, optionally in the form of a solvate, a composition comprising said analogs, their use as medicament, in particular for the treatment of cancer, and a process for their preparation. 

Water soluble 4-azapodophyllotoxin analogs

The present invention relates to a method for treating a Leber congenital amaurosis in a patient harboring the mutation c.2991+1655 A&#x3e;G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A&#x3e;G CEP290 mRNA.

The invention relates to a composition including (1) an anionic macromolecule except nucleic acids, (2) a cationic lip, and (3) a nucleic acid having a size lower than or equal to 200 nucleotides, such as an interference RNA, and to the use thereof in gene therapy.

Vectors including an anionic macromolecule and a cationic lipid for delivering small nucleic acids

The present invention relates to specific regions of the N-terminal portion of the VAR2CSA protein and to the use of such specific regions in the prevention of pregnancy-associated malaria. The invention also provides immunogenic compositions and vaccines that are useful for preventing malaria in pregnant women.

Vaccines against pregnancy-associated malaria

Methods for the treatment of leber congenital amaurosis

The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies.

Use of decorin for increasing muscle mass

The invention relates to the use of fibromodulin and lumican, particularly active fragments thereof, to increase muscle mass, especially in the treatment of muscular dystrophies.

Use of fibromodulin and lumican for increasing muscle mass

The invention relates to using persistent luminescence nanoparticles, functionalised if necessary, in the form of an diagnosis agent for an in vivo optical imaging. Said nanoparticles are preferably consist of a compound selected from a group comprising (1) silicates, aluminates, aluminosilicates, germanates, titanates, oxysulphides, phosphates and vanadates, wherein said compounds contain at least one type of metal oxide, (2) the sulphides comprise at least one metal ion selected from zinc, strontium and calcium, and (3) metal oxides, wherein said compounds is doped with at least one rare earth ion, and possibly with at least one transition metal ion. In a preferred embodiment, the diagnosis agent is used for an organism vascularization imaging. A method and kit for detecting or quantifying in vitro a substance of biological or chemical interest in a sample by using said pre-functionalised nanoparticles are also disclosed.

Persistent luminescence nanoparticles used in the form of a diagnosis agent for in vivo optical imaging

The invention relates to a mutated cell such as a bacteria or yeast in which the thyA gene coding thymidylate synthase includes a nonsense codon, preferably the amber codon, said nonsense codon replacing a codon coding an amino acid and inducing the interruption of thyA gene translation and the auxotrophy of the cell for the thymidine. Advantageously, the endA gene coding the endonuclease 1 and/or the recA gene coding the recombinase is inactivated in said mutated cell. The invention also relates to an expression plasmid including a transgene and a sequence of a suppressing ARM structural gene containing an anticodon that can be paired with the nonsense codon of the thyA gene and is specific of an amino acid capable of restoring the translation of the mutated thyA gene and thereby obtaining a protein of the wild or mutated type having a thymidylate synthase activity. The invention also relates to a method for the multiplication of the expression plasmid.

Plasmic production and expression of recombinant proteins in cells grown without antibiotics

A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.

Purification of a triple helix formation with an immobilized obligonucleotide

Growing community of inventors

Paris, France

Daniel Scherman